目的筛选藏药五味沙棘散(WSP)治疗新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19),的潜在活性成分。方法采用中药系统药理学技术平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP...目的筛选藏药五味沙棘散(WSP)治疗新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19),的潜在活性成分。方法采用中药系统药理学技术平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP)筛选藏药五味沙棘散(沙棘、余甘子、木香、甘草、葡萄)潜在活性成分,采用Swiss Target Prediction预测活性成分的潜在靶点,通过String数据库绘制蛋白质相互作用网络,通过DAVID数据库对WSP作用靶点进行Gene Ontology(GO)功能注释和KEGG通路富集分析,借助Cytoscape 3.7.2构建"药物-成分-靶点"网络。通过Maestro version 11.5软件,将活性成分作为配体与受体血管紧张素转换酶Ⅱ(ACE2)、细胞丝氨酸蛋白酶(TMPRSS2)和COVID-19 3CL水解酶(Mpro)进行分子对接验证。结果 "药物-成分-靶点"网络包含5味药物、29个化合物和32个核心靶点,得到GO功能富集条目225条(p <0.05),KEGG通路富集筛选得到15条信号通路(p <0.05)。分子对接结果显示甘草苷、甘草异黄烷酮、槲皮素、山柰酚等核心化合物与COVID-19靶点结合力最强。结论本研究体现出藏药五味沙棘散"多成分-多靶点-多途径"的作用特点,其活性成分通过与ACE2,TMPRSS2和COVID-19 3CL水解酶结合作用于AKT1、VEGFA、EGFR等靶点,调节MAPK signaling pathway、Toll-like receptor signaling pathway、T cell receptor signaling pathway等多条信号通路,实现对COVID-19肺炎潜在的治疗作用。展开更多
晚近爆发的“新型冠状病毒肺炎”是由新冠状病毒感染所致的疾病,简称“新冠肺炎”。2020年2月11日,世界卫生组织(world health organization,WHO)将之正式命名为Corona Virus Disease-2019(COVID-19)。1新冠状病毒为何首先青睐呼吸道已...晚近爆发的“新型冠状病毒肺炎”是由新冠状病毒感染所致的疾病,简称“新冠肺炎”。2020年2月11日,世界卫生组织(world health organization,WHO)将之正式命名为Corona Virus Disease-2019(COVID-19)。1新冠状病毒为何首先青睐呼吸道已经确认:飞沫传播、接触传播是新冠病毒传播的主要方式(气溶胶传播、粪-口传播是尚未明确的可能传播方式)。相对于人体其他器官,呼吸道始终处于一种与外界直接相互联通的开放状态。因此,亦就成为病毒最易侵入人体的便捷通道。展开更多
新型冠状病毒肺炎(COVID-19)是一种呼吸道疾病,其主要通过呼吸道在人与人间传播,由SARS-CoV-2病毒引起。COVID-19经过传播导致疫病在全世界范围内大流行,快速扩张,对人类的健康及全球的经济发展造成了不可估量的危害。目前研究证据表明,...新型冠状病毒肺炎(COVID-19)是一种呼吸道疾病,其主要通过呼吸道在人与人间传播,由SARS-CoV-2病毒引起。COVID-19经过传播导致疫病在全世界范围内大流行,快速扩张,对人类的健康及全球的经济发展造成了不可估量的危害。目前研究证据表明,COVID-19已发生多次变异,传染性极高,病毒载量增加,COVID-19大流行大大增加了许多患者发生静脉和动脉血栓栓塞事件的风险,因此,全面认识COVID-19血栓风险及治疗进展对新型冠状病毒感染患者的预后极其重要。本文简要叙述COVID-19血栓形成机制,并对血栓危险因素及治疗进展作一系统综述。Novel coronavirus pneumonia (COVID-19) is a respiratory disease that spreads from person to person primarily through the respiratory tract and is caused by the SARS-CoV-2 virus. The spread of COVID-19 has resulted in a global pandemic and rapid expansion of the epidemic, posing an incalculable risk to human health and global economic development. Current research suggests that COVID-19 has undergone multiple mutations, is highly infectious, has an elevated viral load, and that the COVID-19 pandemic has greatly increased the risk of venous and arterial thromboembolic events in many patients;therefore, a comprehensive understanding of the risk of COVID-19 thrombosis and therapeutic advances are extremely important for the prognosis of patients with novel coronavirus infections. This article briefly describes the mechanism of COVID-19 thrombosis and provides a systematic review of thrombotic risk factors and therapeutic advances.展开更多
文摘晚近爆发的“新型冠状病毒肺炎”是由新冠状病毒感染所致的疾病,简称“新冠肺炎”。2020年2月11日,世界卫生组织(world health organization,WHO)将之正式命名为Corona Virus Disease-2019(COVID-19)。1新冠状病毒为何首先青睐呼吸道已经确认:飞沫传播、接触传播是新冠病毒传播的主要方式(气溶胶传播、粪-口传播是尚未明确的可能传播方式)。相对于人体其他器官,呼吸道始终处于一种与外界直接相互联通的开放状态。因此,亦就成为病毒最易侵入人体的便捷通道。
文摘新型冠状病毒肺炎(COVID-19)是一种呼吸道疾病,其主要通过呼吸道在人与人间传播,由SARS-CoV-2病毒引起。COVID-19经过传播导致疫病在全世界范围内大流行,快速扩张,对人类的健康及全球的经济发展造成了不可估量的危害。目前研究证据表明,COVID-19已发生多次变异,传染性极高,病毒载量增加,COVID-19大流行大大增加了许多患者发生静脉和动脉血栓栓塞事件的风险,因此,全面认识COVID-19血栓风险及治疗进展对新型冠状病毒感染患者的预后极其重要。本文简要叙述COVID-19血栓形成机制,并对血栓危险因素及治疗进展作一系统综述。Novel coronavirus pneumonia (COVID-19) is a respiratory disease that spreads from person to person primarily through the respiratory tract and is caused by the SARS-CoV-2 virus. The spread of COVID-19 has resulted in a global pandemic and rapid expansion of the epidemic, posing an incalculable risk to human health and global economic development. Current research suggests that COVID-19 has undergone multiple mutations, is highly infectious, has an elevated viral load, and that the COVID-19 pandemic has greatly increased the risk of venous and arterial thromboembolic events in many patients;therefore, a comprehensive understanding of the risk of COVID-19 thrombosis and therapeutic advances are extremely important for the prognosis of patients with novel coronavirus infections. This article briefly describes the mechanism of COVID-19 thrombosis and provides a systematic review of thrombotic risk factors and therapeutic advances.
